RecruitingNCT04443530

Evaluation of Effectiveness and Safety of Ultimaster™ Tansei™ Stent in Routine Clinical Practice

Evaluation of Effectiveness and Safety of Ultimaster™ Tansei™ Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study

Sponsor

Duk-Woo Park, MD

Enrollment

2,000 participants

Start Date

Sep 17, 2020

Study Type

OBSERVATIONAL

Conditions

Coronary Artery Disease

Summary

This study is to evaluate the effectiveness and safety of Ultimaster Tansei stent in the "real-world" daily practice.

Eligibility

Min Age: 19 Years

Inclusion Criteria3

Patients ≥ 19 years old
Patients receiving Ultimaster™ Tansei™ stents.
The patient or guardian agrees to the study protocol and the schedule of clinical follow-up and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.

Exclusion Criteria3

Patients with a mixture of other drug-eluting stents (DESs)
Terminal illness with life-expectancy ≤1 year.
Patients with cardiogenic shock

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGUltimaster™ Tansei™ stents

Patients receiving Ultimaster™ Tansei™ stents

Locations(11)

Gangwon National Univ. Hospital

Chuncheon, South Korea

Daegu Catholic University Medical Center

Daegu, South Korea

Keimyung University Dongsan Medical Center

Daegu, South Korea

The Catholic University of Korea, Daejeon ST. Mary's Hospital

Daejeon, South Korea

Gangneung Asan Hospital

Gangneung, South Korea

Kwangju Christian Hospital

Kwangju, South Korea

Pusan National University Hospital

Pusan, South Korea

Asan Medical Center

Seoul, South Korea

Kangdong Sacred Heart Hospital

Seoul, South Korea

The Catholic Univ. of Korea Eunpyeong St. Mary's hospital

Seoul, South Korea

St.Carollo Hospital

Suncheon, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04443530

Related Trials

DEBSCAN-IVL. Drug Eluting Balloon or Drug Eluting Stent to Treat CAlcified Nodules After IntraVascular Lithotripsy.

NCT0665783313 locations

Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions

NCT072582901 location

Product Surveillance Registry

NCT01524276395 locations

Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions

NCT0719069016 locations

Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation

NCT0686315512 locations